Authorization to implement the merger plan between Klaria and Karessa granted by the Swedish Companies Registration Office

Report this content

The Swedish Companies Registration Office (the “SCRO”) has granted Klaria Pharma Holding AB (publ) (”Klaria”) (Nasdaq First North Growth Market: KLAR) authorization to implement the merger plan for the merger between Klaria and Karessa Pharma Holding AB (publ) (”Karessa”).

The SCRO is expected to register the merger on Friday March 6, 2020. In connection with the registration of the merger, Karessa will be dissolved and all its assets and liabilities will be transferred to Klaria.

In connection with the registration of the merger by the SCRO the shareholders that are registered in the share register of Karessa will receive merger consideration. Each share in Karessa will be exchanged for 0.6032 new shares in Klaria. Karessa’s shareholders will receive the Klaria shares i.e. the merger consideration on March 9, 2020. Trading in the Klaria share takes place as usual and will not be affected by the merger process.

The nature of this information requires Klaria Pharma Holding AB (publ) to publish it as provided in the Nasdaq First North Growth Markets Rules for Issuers. This information was issued under the supervision of the contact persons below for publication on 3 March 2020 at 08:30 CET.

For more information, visit the  Klaria Pharma Holding website or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
Tel: +46 (0) 8-446 42 99


This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see


Documents & Links